<DOC>
	<DOCNO>NCT02262936</DOCNO>
	<brief_summary>Nocturia , void night , extremely troublesome symptom highly prevalent elderly . Desmopressin treatment nocturia result hyponatremia ( low blood sodium ) , particularly age 65 old . Fesoterodine use treatment overactive bladder ( OAB ) . Recent trial show Fesoterodine effective reduce nocturia . This study aim answer follow : In woman 65 old severe nocturia , Fesoterodine effective Desmopressin reduce number night time void ? Does Fesoterodine better side effect profile compare Desmopressin ? The study design 12 week randomize double-blinded trial Fesoterodine Desmopressin treatment severe nocturia woman age 65 old . This conducted Urogynecology Unit Mount Sinai Hospital ( MSH ) Baycrest . A 3 day void diary Nocturia , Nocturnal Enuresis Sleep-interruption Questionnaire ( NNES-Q ) complete baseline week 12 . The primary outcome number night time void Fesoterodine group compare Desmopressin group , 12 week start treatment . Secondary outcome include change NNES-Q score safety medication . This study expect show , woman 65 old severe nocturia , Fesoterodine effective reduce number night time void , reduce volume void urine , increase duration sleep prior first nocturnal void improve quality life relative Desmopressin . Fesoterodine also well tolerate , few significant adverse event , relative Desmopressin .</brief_summary>
	<brief_title>Comparison Between Desmopressin Fesoterodine Treatment Night Time Voiding Women Aged 65 Older</brief_title>
	<detailed_description>This study include female patient 65 year old Urogynecology Units Mount Sinai Hospital ( MSH ) Baycrest . It 12 week prospective , randomized double-blind trial compare treatment nocturia use Fesoterodine Desmopressin . Patients agree participate study receive start dose either Fesoterodine 4mg tablet bedtime Desmopressin 0.1mg tablet bedtime . After 4 week , patient minimal improvement symptom significantly affect side effect , patient option increase dose medication 8mg Fesoterodine 0.2mg Desmopressin . This decision make patient physician together . Patients undergo block randomization pharmacy . All patient investigator blind treatment group . Patients follow 12 week , visit 4 12 week . Patients also urine culture uroflowmetry measurement post-void residual visit , per clinic standard care . Venipuncture monitor electrolyte level do baseline , 1 week randomization monthly end study . If patient choose increase dose 4 week visit , electrolyte level repeat one week dose adjustment monthly end study . The last follow 12 week , 3 day void diary NNES-Q collect .</detailed_description>
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Menopausal female patient age 65 year old Patients severe nocturia , define wake void 3 time night due urge void Patients capable understanding sign consent form full discussion research , nature treatment , risk benefit Urinary tract infection chronic inflammation interstitial cystitis bladder stone Urinary gastric retention Narrowangle glaucoma von Willebrand 's disease Chronic severe constipation history gastrointestinal obstructive disease Untreated congestive heart failure venous insufficiency Untreated hypertension tachycardia Untreated renal liver disease Untreated diabetes mellitus insipidus Unexplained untreated electrolyte disturbance Any clinical condition opinion investigator would allow safe completion study Current use diuretic untreated electrolyte disturbance Patients take drug know strong CYP3A4 inhibitor ( protease inhibitor , ketoconazole , clarithromycin ) strong CYP3A4 inducer ( carbamazepine , phenytoin , St. John 's Wort ) use regular basis Patients take anticholinergic antispasmodic medication comply minimum 14 day washout period Previous fail therapy Fesoterodine Desmopressin Hypersensitivity intolerance Fesoterodine Desmopressin Hypersensitivity soya , peanut lactose Clinically significant outlet obstruction determine investigator Patients Post Void Residual ( PVR ) &gt; 100 ml Patients MiniMental State Exam ( MMSE ) &lt; 24</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Aged</keyword>
	<keyword>Deamino Arginine Vasopressin</keyword>
	<keyword>Fesoterodine</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>